Publications
5674 Results
- Journal / Conference
- Blood 100(11):210a(#790)
- Year
- 2002
- Research Committee(s)
- Leukemia
Time to first progression is the best predictor of survival duration in SWOG standard dose chemotherapy studies
- Journal / Conference
- Int J Radiat Oncol Biol Phys 54(2):103-104(#174)
- Year
- 2002
- Research Committee(s)
- Lung
Analysis of prognostic factors in Southwest Oncology Group stage III non-small cell lung cancer trials requiring pre-treatment histological assessment of mediastinal lymph nodes
- Journal / Conference
- Int J Radiat Oncol Biol Phys 54(2):2(#3)
- Year
- 2002
- Research Committee(s)
- Head and Neck
- Study Number(s)
- SWOG-9515 (RTOG-9501)
Patterns of failure for resected advanced head & neck cancer treated by concurrent chemotherapy and radiation therapy: an analysis of RTOG 9501/Intergroup Phase III trial
- Journal / Conference
- Journal of Clinical Oncology 20(8):2209-2210
- Year
- 2002
- Research Committee(s)
- Melanoma
- Study Number(s)
- SWOG-9512 (E1694)
In reply to the Letter to the Editor: Sentinel-node technique will change the design of clinical trials in malignant melanoma
- Journal / Conference
- Blood 100(11):598a(#2351)
- Year
- 2002
- Research Committee(s)
- Myeloma
- Study Number(s)
- SWOG-9321
A simple classification to identify poor-risk untreated myeloma
- Journal / Conference
- American Head and Neck Society meeting (COSM):(#168)
- Year
- 2002
- Research Committee(s)
- Head and Neck
- Study Number(s)
- SWOG-9201 (RTOG-91-11)
Outcome for salvage total laryngetomy (TL) following organ preservation therapy: the Radiation Therapy Oncology Group trial 91-11
- Journal / Conference
- Int J Radiat Oncol Biol Phys 54(2):2-3(#4)
- Year
- 2002
- Research Committee(s)
- Head and Neck
- Study Number(s)
- SWOG-9201 (RTOG-91-11)
Larynx preservation and tumor control in stage III and IV laryngeal cancer: a three-arm randomized Intergroup trial; RTOG 91-11
- Journal / Conference
- Journal of Clinical Oncology 20(16):3369-3375
- Year
- 2002
- Research Committee(s)
- Genitourinary
- Study Number(s)
- SWOG-9452 (INT-0159) (CALGB 9480)
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of Intergroup 0159, Cancer and Leukemia Group B 9480
- Journal / Conference
- ASCO/Molecular Therapeutics Symposium, San Diego CA :#52
- Year
- 2002
A phase I study of a HER-2/neu intracellular protein (HER2 ICD) vaccine in patients with HER2 overexpressing breast or ovarian cancer
- Journal / Conference
- Journal of the American Medical Association 287(3):321-328
- Year
- 2002
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- SWOG-9411